Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects

Nature Genetics

Volumn 26, Issue 1, 2000, Pages 109-113

  Reilly, Karlyne M ^a   Loisel, Dagan A ^a,d   Bronson, Roderick T ^b   McLaughlin, Margaret E ^a,c,d   Jacks, Tyler ^a,d  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTOMA; BRAIN CANCER; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; GLIOBLASTOMA; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; ONCOGENE; OPTIC NERVE GLIOMA; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

AGE FACTORS; ALLELES; ANIMALS; ASTROCYTOMA; BRAIN NEOPLASMS; CEREBELLUM; CULTURE TECHNIQUES; FEMALE; GENES, NEUROFIBROMATOSIS 1; GENES, P53; GENOTYPE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, MUTANT STRAINS; MICE, NUDE; MUTATION; NECROSIS; NEOPLASM TRANSPLANTATION; NERVE TISSUE PROTEINS; NEUROFIBROMIN 1; PITUITARY GLAND; POLYMERASE CHAIN REACTION; SPECIES SPECIFICITY; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 0033812187     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/79075     Document Type: Article

References (27)

1. Danks, R. et al. Transformation of astrocytes in transgenic mice expressing SV40 T antigen under the transcriptional control of the glial fibrillary acidic protein promoter. Cancer Res. 55, 4302-4310 (1995).
2. Holland, E., Hively, W., DePinho, R. & Varmus, H. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev. 12, 3675-3685 (1998).
3. Weissenberger, J. et al. Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice. Oncogene 14, 2005-2013 (1997).
4. Huson, S. & Hughes, R. The Neurofibromatoses: A Pathogenetic and Clinical Overview (Chapman & Hall Medical, London, 1994).
5. Sorensen, S.A., Mulvihill, J.J. & Nielsen, A. Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N. Engl. J. Med. 314, 1010-1015 (1986).
6. Watanabe, K. et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin. Cancer Res. 3, 523-530 (1997).
7. Watanabe, K. et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 6, 217-223 (1996).
8. van Meyel, D.J. et al. p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. J. Natl Cancer Inst. 86, 1011-1017 (1994).
9. Rasheed, B.K. et al. Alterations of the TP53 gene in human gliomas. Cancer Res. 54, 1324-1330 (1994).
10. Lang, F.F., Miller, D.C., Koslow, M. & Newcomb, E.W. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J. Neurosurg. 81, 427-436 (1994).
11. Cichowski, K. et al. Mouse models of tumor development in neurofibromatosis type 1. Science 286, 2172-2176 (1999).
12. Vogel, K. et al. Mouse tumor model for neurofibromatosis type 1. Science 286, 2176-2179 (1999).
13. Rizvi, T. et al. Region-specific astrogliosis in brains of mice heterozygous for mutations in the neurofibromatosis type 1 (Nf1) tumor suppressor. Brain Res. 816, 111-123 (1999).
14. Gutmann, D. et al. Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation. Oncogene 18, 4450-4459 (1999).
15. Tischler, A., Shih, T., Williams, B. & Jacks, T. Characterization of pheochromocytomas in a mouse strain with a targeted disruptive mutation of the neurofibromatosis gene Nf1. Endocrine Pathol. 6, 323-335 (1995).
16. Kleihues, P. & Cavenee, W. Pathology and Genetics of Tumours of the Nervous System (International Agency for Research on Cancer, Lyon, 1997).
17. Kleihues, P., Burger, P.C. & Scheithauer, B.W. The new WHO classification of brain tumours. Brain Pathol. 3, 255-268 (1993).
18. Scherer, H. The forms of growth in gliomas and their practical significance. Brain 63, 1-35 (1940).
19. Marsden, H.B., Kumar, S., Kahn, J. & Anderton, B.J. A study of glial fibrillary acidic protein (GFAP) in childhood brain tumours. Int. J. Cancer 31, 439-445 (1983).
20. Gould, V.E. et al. Synaptophysin: a novel marker for neurons, certain neuroendocrine cells, and their neoplasms. Hum. Pathol. 17, 979-983 (1986).
21. Bonner, R. et al. Laser capture microdissection: molecular analysis of tissue. Science 278, 1481-1483 (1997).
22. Easton, D., Ponder, M., Huson, S. & Ponder, B. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am. J. Hum. Genet. 53, 305-313 (1993).
23. Jacks, T. Tumor predisposition in mice heterozygous for a targeted mutation in NF1. Nature Genet. 7, 353-361 (1994).
24. Menon, A. et al. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc. Natl Acad. Sci. USA 87, 5435-5439 (1990).
25. Jacks, T. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1-7 (1994).
26. Lowe, S., Jacks, T., Housman, D. & Ruley, H. Abrogation of oncogene-associated apoptosis allows transformation of p55-deficient cells. Proc. Natl Acad. Sci. USA 91, 2026-2030 (1994).
27. Brugarolas, J., Bronson, R. & Jacks, T. p21 is a critical CDK2 regulator essential for proliferation control in Rb-deficient cells. J. Cell Biol. 141, 503-514 (1998).